middle.news
Can Cynata’s Late-Stage Trials Unlock Cell Therapy’s Commercial Future?
1:53pm on Friday 31st of October, 2025 AEDT
•
Biotechnology
Read Story
Can Cynata’s Late-Stage Trials Unlock Cell Therapy’s Commercial Future?
1:53pm on Friday 31st of October, 2025 AEDT
Key Points
Phase 2 acute Graft versus Host Disease trial nearing enrolment completion
Phase 3 osteoarthritis trial final patient visit expected November 2025
Key clinical data readouts anticipated in Q2 calendar year 2026
Cash runway secured through mid-2026 with $3.2 million cash and $1.7 million R&D rebate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE